GSK

Latest news

• GSK | 10/2/26 (opens in a new tab)

  ktnv.com · Oct 2, 2026

• Voting rights update pressures GSK stock near GBX1,847 resistance (opens in a new tab)

  Traders Union · Oct 2, 2026

• The Technical Signals Behind (GSK) That Institutions Follow (opens in a new tab)

  Stock Traders Daily · Oct 1, 2026

• Kristian Jensen: Begining a New Chapter at GSK After Novartis Journey (opens in a new tab)

  Oncodaily · Oct 1, 2026

• GSK (GSK) reports 4.05B voting rights, with 271M shares held in treasury (opens in a new tab)

  Stock Titan · Oct 1, 2026

• GSK adds liver candidate from Wave RNA partnership (opens in a new tab)

  European Biotechnology Magazine · Oct 1, 2026

• What's behind GSK's latest 1.8% stock pullback? (opens in a new tab)

  Traders Union · Oct 1, 2026

• GSK Updates Market on Total Voting Rights and Share Capital (opens in a new tab)

  TipRanks · Oct 1, 2026

• 
  Abbott Stock And Other Healthcare Dividend Names Built For Supply Chain Shocks (opens in a new tab)

  Simply Wall St. · Oct 1, 2026

• GSK plc : JP Morgan reiterates its Sell rating (opens in a new tab)

  marketscreener.com · Oct 1, 2026

• Tyler Reynolds Joins GSK as Director, Digital Medicine (opens in a new tab)

  BioBuzz · Oct 1, 2026

• Why Did Haleon (LSE:HLN) Draw Attention As GSK Completed Its Exit This Week? (opens in a new tab)

  kalkinemedia.com · Oct 1, 2026

• How Is GSK (LSE:GSK) Stock Reacting This Week To Its Wave Life Sciences Liver Candidate? (opens in a new tab)

  kalkinemedia.com · Oct 1, 2026

• Wave lands USD 12m as GSK advances SpiNA siRNA program (opens in a new tab)

  AllSci · Oct 1, 2026

• Why is GSK stock down today? Selloff intensifies, key levels to watch (opens in a new tab)

  Traders Union · Oct 1, 2026

• GSK (LSE:GSK) Expands TB Research as Gates Funding Continues (opens in a new tab)

  kalkinemedia.com · Oct 1, 2026

• GSK Pharma stock enters a results blackout before Q2 FY27 (opens in a new tab)

  ad-hoc-news.de · Oct 1, 2026

• Wave Life announces GSK’s selection of siRNA program to transition to GSK (opens in a new tab)

  TipRanks · Oct 1, 2026

• GSK (LSE:GSK) Gets Extended Gates Funding For Tuberculosis Drug Research (opens in a new tab)

  Simply Wall Street · Oct 1, 2026

• GSK continues to stock up on Wave's RNA drugs with liver-focused program (opens in a new tab)

  Fierce Biotech · Sep 30, 2026

• Does GSK (LSE:GSK) Have Fresh Momentum As London Pharma Gets A Lift From Cancer Dealmaking With FTSE 100 In Focus? (opens in a new tab)

  Kalkine Media · Sep 30, 2026

• GSK selects Wave Life Sciences hepatology candidate By Investing.com (opens in a new tab)

  Investing.com UK · Sep 30, 2026

• Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development (opens in a new tab)

  Yahoo Finance · Sep 30, 2026

• GSK (LSE:GSK) The Latest Update Raises A Bigger Question (opens in a new tab)

  Sep 30, 2026

• Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies (opens in a new tab)

  Sep 30, 2026

• Can GSK shares outperform FTSE 100 index over the long run? (opens in a new tab)

  Interactive Investor · Sep 30, 2026

• Spotlight On: GSK's HBV hopeful tops FDA's October agenda (opens in a new tab)

  FirstWord Pharma · Sep 29, 2026

• Re-entering the Dragon: GSK returns to China after 12 years in blood cancer drug push (opens in a new tab)

  This is Money · Sep 29, 2026

• GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated (opens in a new tab)

  Proactive financial news · Sep 29, 2026

• GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? (opens in a new tab)

  Sep 29, 2026